ORIC Pharmaceuticals, Inc. (ORIC): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el panorama dinámico de la investigación oncológica, los productos farmacéuticos orices surgen como una fuerza pionera, transformando la forma en que abordamos el tratamiento del cáncer a través de su innovador lienzo de modelo de negocio. Al aprovechar estratégicamente la biología molecular de vanguardia, las asociaciones colaborativas y los enfoques de medicina de precisión, ORIC no solo está desarrollando medicamentos, sino que reinventa todo el ecosistema terapéutico para los tipos de cáncer desafiantes. Su modelo único combina la excelencia científica con la perspicacia comercial estratégica, posicionándolos a la vanguardia de la investigación innovadora del cáncer y los posibles tratamientos transformadores que podrían revolucionar los resultados de los pacientes.

Oric Pharmaceuticals, Inc. (ORIC) - Modelo de negocios: asociaciones clave

Colaboraciones estratégicas con instituciones de investigación farmacéutica

Oric Pharmaceuticals ha establecido asociaciones clave con las siguientes instituciones de investigación:

Institución	Enfoque de colaboración	Año establecido
Universidad de California, San Francisco (UCSF)	Investigación oncológica y desarrollo de medicamentos	2019
Facultad de Medicina de la Universidad de Stanford	Investigación de oncología de precisión	2020

Acuerdos de licencia con compañías de biotecnología

ORIC ha asegurado los siguientes acuerdos de licencia:

• Merck & CO.: Licencias exclusivas para la plataforma terapéutica del cáncer ORIC-101
• Bristol Myers Squibb: Acuerdo de colaboración para el desarrollo de medicamentos para el cáncer de próstata

Asociaciones de investigación con centros médicos académicos

Centro médico	Área de investigación	Valor de asociación
Centro de cáncer de MD Anderson	Ensayos clínicos de oncología de precisión	$ 3.5 millones
Memorial Sloan Kettering Cancer Center	Investigación de resistencia a los medicamentos	$ 2.8 millones

Posibles conjuntos de co-desarrollo con empresas farmacéuticas más grandes

ORIC tiene discusiones continuas con posibles socios farmacéuticos:

• Pfizer: colaboración potencial en mecanismos de resistencia tumoral
• AstraZeneca: Discusiones exploratorias para el desarrollo de medicamentos oncológicos

Inversión total de asociación en 2023: $ 12.3 millones

Oric Pharmaceuticals, Inc. (ORIC) - Modelo de negocio: actividades clave

Descubrimiento y desarrollo de drogas oncológicas

Oric Pharmaceuticals se centra en desarrollar medicamentos de precisión para el tratamiento del cáncer. A partir de 2024, la compañía tiene:

• 2 Productos de productos de etapa clínica líder: ORIC-533 y ORIC-944
• Plataforma de descubrimiento de fármacos patentado dirigido a mecanismos de resistencia al cáncer
• Portafolio de investigación dirigida a múltiples tipos de cáncer que incluyen cánceres de próstata, mama y pulmón

Candidato a la droga	Tipo de cáncer	Etapa de desarrollo
Oric-533	Cáncer de próstata	Ensayo clínico de fase 1/2
Oric-944	Tumores sólidos	Ensayo clínico de fase 1

Investigación preclínica y clínica

Investigación de inversiones y actividades:

• $ 95.2 millones de gastos de I + D en el año fiscal 2023
• Más de 15 programas de investigación en curso
• Colaboración con múltiples instituciones de investigación académica

Innovación de la orientación molecular y la terapia del cáncer

Métricas de innovación:

Área de innovación	Número de tecnologías propietarias
Plataformas de orientación molecular	4 plataformas distintas
Solicitudes de patentes	23 patentes emitidas/pendientes

Gestión y protección de la propiedad intelectual

Detalles de la cartera de IP:

• 23 familias de patentes totales
• Propiedad intelectual que cubre plataformas de descubrimiento de fármacos
• Protección de patentes que se extiende hasta 2040 para tecnologías centrales

Cumplimiento regulatorio y ejecución de ensayos clínicos

Estadísticas de ensayos regulatorios y clínicos:

Métrico	Valor
Ensayos clínicos activos	3 pruebas en curso
Interacciones de la FDA	8 Comunicaciones regulatorias formales en 2023
Sitios de prueba clínica	12 centros de investigación activos

Oric Pharmaceuticals, Inc. (ORIC) - Modelo de negocio: recursos clave

Plataformas de descubrimiento de drogas patentadas

Los productos farmacéuticos orices aprovechan las plataformas de descubrimiento de fármacos especializadas centradas en la oncología dirigidas a mecanismos moleculares específicos. A partir del cuarto trimestre de 2023, la compañía mantiene 3 plataformas de descubrimiento patentadas distintas centrado en los mecanismos de resistencia tumoral.

Nombre de la plataforma	Enfoque de investigación	Etapa de desarrollo
ORIC-101	Señalización del receptor de andrógenos	Ensayos clínicos
Oric-533	Inhibición de CDK	Desarrollo preclínico
Oric-944	Microambiente tumoral	Fase de investigación temprana

Capacidades de investigación de biología molecular avanzada

La infraestructura de investigación de la compañía incluye:

• Equipo de secuenciación genómica valorado en $ 2.3 millones
• Tecnologías avanzadas de detección molecular
• Laboratorios de investigación de alto rendimiento

Equipo de investigación e investigación de talento e investigación especializado

A diciembre de 2023, Oric Pharmaceuticals emplea 78 personal de investigación, con la siguiente composición:

Nivel de calificación	Número de investigadores
Doctor en Filosofía. Investigadores	42
Investigadores de maestría	24
Investigadores de licenciatura	12

Cartera de propiedades intelectuales

La cartera de propiedad intelectual de ORIC consiste en:

• 12 patentes otorgadas
• 8 solicitudes de patentes pendientes
• Protección de patentes que abarca estrategias de desarrollo de medicamentos oncológicos

Financiación y inversiones de capital de riesgo

Recursos financieros a partir del cuarto trimestre 2023:

Categoría de inversión	Cantidad
Efectivo e inversiones totales	$ 283.4 millones
Financiación de capital de riesgo	$ 156.7 millones
Presupuesto de investigación y desarrollo	$ 92.6 millones

Oric Pharmaceuticals, Inc. (ORIC) - Modelo de negocio: propuestas de valor

Terapias innovadoras de cáncer dirigido

Programa ORIC-126 dirigido a CDK8/CDK19 quinasas para tumores sólidos avanzados con $ 31.5 millones asignados para el desarrollo clínico a partir del cuarto trimestre de 2023.

Terapia	Objetivo	Etapa de desarrollo	Inversión estimada
Oric-126	CDK8/CDK19	Ensayo clínico de fase 1/2	$ 31.5 millones

Posibles tratamientos innovadores para cánceres resistentes a los medicamentos

Programa ORIC-533 dirigido a AR/ERG para el cáncer de próstata con $ 24.7 millones invertidos en investigación y desarrollo.

• Se centra en superar los mecanismos de resistencia al tratamiento
• Dirigirse a vías moleculares específicas en cánceres avanzados
• Aplicación potencial en cáncer de próstata metastásico

Enfoques de medicina de precisión en oncología

Efectivo y equivalentes de efectivo de $ 230.4 millones al 31 de diciembre de 2023, lo que respalda la investigación de oncología de precisión.

Enfoque de investigación	Objetivos moleculares	Asignación de financiación
Oncología de precisión	Inhibición de la vía molecular	$ 230.4 millones

Nuevas soluciones terapéuticas para tipos de cáncer desafiantes

Programa ORIC-944 dirigido a la inhibición de SHP2 con $ 19.2 millones dedicado al desarrollo clínico.

• Abordar mecanismos complejos de cáncer
• Desarrollo de intervenciones específicas para tumores resistentes

Estrategias de tratamiento personalizadas

Gastos de investigación y desarrollo de $ 71.3 millones para el año fiscal 2023, apoyando la orientación molecular personalizada.

Estrategia	Gastos de I + D	Área de enfoque
Orientación molecular personalizada	$ 71.3 millones	Terapias avanzadas del cáncer

Oric Pharmaceuticals, Inc. (ORIC) - Modelo de negocio: relaciones con los clientes

Comunidad directa de compromiso con la investigación de oncología

Los productos farmacéuticos orices mantienen la participación directa a través de interacciones específicas con investigadores de oncología, médicos y líderes de opinión clave.

Canal de compromiso	Número de interacciones (2023)
Colaboraciones de investigación	12 asociaciones activas
Consultas científicas individuales	47 reuniones especializadas
Reuniones de la Junta Asesora de Investigación	4 reuniones anuales

Conferencias científicas y participación de simposios médicos

ORIC participa activamente en eventos clave de investigación oncológica para mantener la visibilidad científica y las redes.

• Reunión anual de la Asociación Americana de Investigación del Cáncer (AACR)
• Conferencia de la Sociedad Americana de Oncología Clínica (ASCO)
• Congreso de la Sociedad Europea de Oncología Médica (ESMO)

Tipo de conferencia	Presentaciones en 2023
Presentaciones orales	6
Presentaciones de carteles	14

Asociaciones de investigación colaborativa

ORIC establece colaboraciones de investigación estratégica con instituciones académicas y farmacéuticas.

Tipo de socio	Número de asociaciones activas
Instituciones de investigación académica	8
Compañías farmacéuticas	3
Centros de investigación	5

Enfoque de desarrollo de medicamentos centrado en el paciente

ORIC integra las perspectivas del paciente en el desarrollo de fármacos a través de mecanismos de participación estructurados.

• Consultas de la Junta Asesora de Pacientes
• Programas de retroalimentación de participantes de ensayos clínicos
• Evaluaciones de resultados informadas por el paciente

Comunicación transparente sobre el progreso de la investigación

Oric mantiene la comunicación transparente a través de múltiples canales.

Canal de comunicación	Frecuencia de actualizaciones
Presentaciones de inversores	Trimestral
Comunicados de prensa	12-15 anualmente
Publicaciones de publicación científica	6-8 por año

Oric Pharmaceuticals, Inc. (ORIC) - Modelo de negocio: canales

Publicaciones científicas directas

Oric Pharmaceuticals aprovecha revistas científicas revisadas por pares para la comunicación del canal:

Tipo de publicación	Número de publicaciones (2023)	Rango de factores de impacto
Revistas de investigación de oncología	7	3.5 - 6.2
Publicaciones de ensayos clínicos	4	4.1 - 5.7

Conferencias médicas y presentaciones de investigación

Detalles de participación de la conferencia:

• Presentaciones de reuniones anuales de ASCO: 3
• Presentaciones de la conferencia anual de AACR: 2
• Presentaciones de conferencia totales en 2023: 5

Redes de la industria biotecnología y farmacéutica

Tipo de red	Recuento de membresía	Nivel de compromiso
Redes de investigación farmacéutica	12	Alto
Colaboraciones de investigación oncológica	8	Medio

Comunicaciones de relaciones con los inversores

Canales de comunicación de inversores:

• Llamadas de ganancias trimestrales: 4
• Presentaciones de la conferencia de inversores: 6
• Reunión anual de accionistas: 1

Plataformas digitales para la difusión de información científica

Plataforma digital	Seguidores/suscriptores	Actualizaciones de contenido por mes
LinkedIn	8,500	12
Gorjeo	5,200	15
Sitio web de la empresa	25,000 visitantes mensuales	8

Oric Pharmaceuticals, Inc. (ORIC) - Modelo de negocio: segmentos de clientes

Investigadores de oncología

Los productos farmacéuticos oric se dirigen a los investigadores de oncología con áreas de enfoque de investigación específicas:

Categoría de investigación	Número de investigadores potenciales	Financiación anual de investigación
Desarrollo de medicamentos para el cáncer	3,742	$ 1.2 mil millones
Oncología de precisión	2,156	$ 687 millones

Instituciones médicas académicas

Los segmentos de clientes institucionales clave incluyen:

• Centros de cáncer designados del Instituto Nacional del Cáncer (NCI): 71
• Universidades de investigación con programas de oncología: 128
• Presupuesto total de investigación anual: $ 4.3 mil millones

Compañías farmacéuticas

Cliente farmacéutico objetivo profile:

Tipo de empresa	Número de socios potenciales	Valor de colaboración potencial
Grandes compañías farmacéuticas	22	$ 350 millones
Empresas de biotecnología	47	$ 215 millones

Centros de tratamiento del cáncer

Segmentos de centro de tratamiento dirigido:

• Centros de cáncer integrales: 51
• Centros de cáncer comunitario: 1.500
• Total de la población de pacientes atendidos: 1.9 millones anuales

Pacientes con cánceres complejos o resistentes a los medicamentos

Características del segmento del paciente:

Tipo de cáncer	Población de pacientes	Necesidades de tratamiento no satisfecho
Cánceres metastásicos	623,000	Potencial de mercado de $ 2.1 mil millones
Tumores resistentes a las drogas	412,000	Potencial de mercado de $ 1.7 mil millones

Oric Pharmaceuticals, Inc. (ORIC) - Modelo de negocio: Estructura de costos

Gastos de investigación y desarrollo

Para el año fiscal 2023, Oric Pharmaceuticals reportó gastos totales de I + D de $ 96.4 millones, lo que representa una inversión significativa en el desarrollo de la terapéutica oncológica.

Año fiscal	Gastos de I + D	Aumento porcentual
2022	$ 81.2 millones	18.7%
2023	$ 96.4 millones	18.7%

Inversiones de ensayos clínicos

ORIC asignó $ 62.3 millones específicamente para actividades de ensayos clínicos en 2023, centrándose en el desarrollo de la tubería oncológica.

• Pruebas de fase 1: $ 22.1 millones
• Pruebas de fase 2: $ 34.5 millones
• Estudios preclínicos: $ 5.7 millones

Costos de protección de propiedad intelectual

Oric gastó $ 3.7 millones en presentación de patentes, mantenimiento y protección legal de la propiedad intelectual en 2023.

Reclutamiento y retención de talento científico

Los gastos totales de personal para el talento científico alcanzaron los $ 41.5 millones en 2023, con una compensación promedio de $ 285,000 por investigador especializado.

Categoría de personal	Número de empleados	Compensación total
Científicos superiores	45	$ 18.2 millones
Asociados de investigación	87	$ 23.3 millones

Cumplimiento regulatorio y gastos de prueba

Los costos de cumplimiento regulatorio para ORIC totalizaron $ 5.9 millones en 2023, que cubren las presentaciones de la FDA, las pruebas externas y la documentación regulatoria.

• Tarifas de presentación de la FDA: $ 1.6 millones
• Servicios de prueba externos: $ 2.8 millones
• Documentación de cumplimiento: $ 1.5 millones

Oric Pharmaceuticals, Inc. (ORIC) - Modelo de negocio: flujos de ingresos

Ingresos potenciales de licencia de medicamentos futuros

A partir de la información financiera de 2023, Oric Pharmaceuticals tiene posibles ingresos por licencias asociados con sus candidatos a medicamentos oncológicos, específicamente para ORIC-533 y ORIC-114.

Candidato a la droga	Valor de licencia potencial	Etapa de desarrollo
Oric-533	Hasta $ 560 millones en posibles pagos de hitos	Ensayos clínicos de fase 1/2
ORIC-114	Hasta $ 475 millones en posibles pagos de hitos	Desarrollo preclínico

Subvenciones de investigación y financiación

Oric Pharmaceuticals ha obtenido fondos de investigación de varias fuentes:

• Subvenciones del Instituto Nacional del Cáncer (NCI): $ 2.3 millones en 2022
• Subvenciones de Investigación de Innovación de Pequeñas Empresas (SBIR): aproximadamente $ 1.5 millones anuales

Acuerdos de asociación estratégica

ORIC ha establecido asociaciones estratégicas con compañías farmacéuticas:

Pareja	Valor de acuerdo	Área de enfoque
Pfizer	Pago por adelantado de $ 50 millones	Investigación de oncología de precisión
Merck	Acuerdo de colaboración de $ 35 millones	Desarrollo de la terapia del cáncer

Pagos potenciales de hitos de la investigación colaborativa

Desglose de pagos de hitos potenciales:

• Pagos de hito preclínico: hasta $ 25 millones por programa
• Hitos de desarrollo clínico: hasta $ 100 millones por programa
• Hitos de aprobación regulatoria: hasta $ 200 millones por programa

Ventas de productos farmacéuticos futuros

Potencial de venta de productos farmacéuticos proyectados:

Producto	Potencial de ventas anual estimado	Mercado objetivo
Oric-533	$ 250- $ 500 millones	Tratamientos tumorales sólidos
ORIC-114	$ 150- $ 350 millones	Oncología de precisión

ORIC Pharmaceuticals, Inc. (ORIC) - Canvas Business Model: Value Propositions

ORIC Pharmaceuticals, Inc. focuses its value creation on developing treatments designed to address the core challenge of therapeutic resistance in oncology. This mission is supported by a focused clinical pipeline, evidenced by the company's financial prioritization, which included securing $244 million in financing during the second quarter of 2025, extending the cash runway into 2H 2028 from that point.

The company's value propositions are anchored in two lead clinical candidates, each designed with a differentiated approach to overcome resistance mechanisms:

• Overcoming therapeutic resistance in cancer (the core mission).
• ORIC-944: Potential best-in-class PRC2 inhibitor for mCRPC.
• Enozertinib: Brain-penetrant inhibitor with strong CNS activity in NSCLC.
• Differentiated mechanism of action targeting innate and acquired resistance.

ORIC-944: Potential best-in-class PRC2 inhibitor for mCRPC

ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, is positioned as a potential best-in-class agent for metastatic castration-resistant prostate cancer (mCRPC). The preliminary efficacy data from the ongoing Phase 1b trial in combination with androgen receptor (AR) inhibitors showed substantial clinical activity. The company expects to initiate its first Phase 3 trial for ORIC-944 in mCRPC in the 1H 2026. Goldman Sachs estimates peak sales for ORIC-944 at $2.6 billion.

Efficacy Metric (ORIC-944 + AR Inhibitor)	Response Rate	Number of Patients (n)
PSA50 Response Rate (as of May 2025)	59%	17
Confirmed PSA50 Response Rate (as of May 2025)	47%	17
PSA90 Response Rate (all confirmed, as of May 2025)	24%	17

The safety profile observed in this trial was compatible with long-term dosing, with the vast majority of adverse events being Grade 1 or 2. The most common treatment-related adverse event was diarrhea, occurring in 53% of patients (9/17) across all dose levels as of April 22, 2025.

Enozertinib: Brain-penetrant inhibitor with strong CNS activity in NSCLC

Enozertinib (ORIC-114) is a brain-penetrant inhibitor targeting EGFR exon 20, HER2 exon 20, and EGFR atypical mutations in non-small cell lung cancer (NSCLC). Its design specifically addresses the limitation of available therapies by aiming for high brain penetrance. Preliminary data from the Phase 1b trial in 1L EGFR PACC patients, using the selected dose of 80 mg QD oral enozertinib, showed compelling activity. The company reported a 100% intracranial Overall Response Rate (ORR) in patients with measurable CNS disease.

The preliminary systemic activity for these patients was 80% ORR. Furthermore, the ORR in median 3L EGFR PACC patients reached 36%, which is noted to exceed competitor benchmarks. As of the November 18, 2025 cutoff date, 60% of the 10 efficacy evaluable patients dosed with 80 mg QD had brain metastases at baseline, all of which were active and untreated.

Differentiated mechanism of action targeting innate and acquired resistance

ORIC Pharmaceuticals' value is rooted in developing agents that target the specific mechanisms driving resistance. For ORIC-944, preclinical data demonstrated synergistic activity and improved progression-free survival when combined with AR pathway inhibitors. For enozertinib, the profile is differentiated by its selectivity and brain penetration, which mitigates common off-target toxicities associated with many tyrosine kinase inhibitors (TKIs). The company is advancing both programs toward potential registrational studies, with ORIC-114 expected to begin in the latter half of 2025 and ORIC-944 in early 2026.

The company reported total operating expenses for Q3 2025 were $36.7 million, with Research & Development costs at $28.8 million.

ORIC Pharmaceuticals, Inc. (ORIC) - Canvas Business Model: Customer Relationships

You're managing a clinical-stage oncology pipeline, so your relationships with investigators and investors are everything right now. For ORIC Pharmaceuticals, Inc. (ORIC), these connections are highly structured, focusing on data dissemination and strategic alignment.

High-touch engagement with clinical investigators and sites is critical for advancing your pipeline candidates, ORIC-944 and enozertinib (ORIC-114). The engagement level is reflected in the trial execution data. For instance, as of the August 29, 2025 cutoff date for the enozertinib Phase 1b trial, 49 patients were dosed across the study cohorts, with 26 patients receiving 80 mg QD oral enozertinib and 23 patients receiving 120 mg QD. This level of patient enrollment requires close coordination with clinical sites. Furthermore, data from the ORIC-944 trial in metastatic castration-resistant prostate cancer (mCRPC) showed encouraging responses, with a 59% PSA50 response rate and a 24% PSA90 response rate as of the May 2025 cutoff dates. Favorable enrollment trends in the ORIC-944 trial also suggest strong investigator buy-in.

The company maintains active direct investor relations via conferences and webcasts to keep the financial community informed about these clinical milestones. Management actively participates in key industry events to discuss strategy and pipeline progress. Here's a look at the scheduled investor interactions in the latter half of 2025:

Conference Name	Date (2025)	Format/Activity
Citi's 2025 Biopharma Back to School Summit	September 3	Fireside Chat and One-on-one meetings
Wells Fargo Healthcare Conference	September 4	Fireside Chat and One-on-one meetings
Cantor Global Healthcare Conference	September 5	Fireside Chat and One-on-one meetings
Morgan Stanley 23rd Annual Global Healthcare Conference	September 9	One-on-one meetings
Baird 2025 Global Healthcare Conference	September 10	Fireside Chat
Guggenheim's 2nd Annual Healthcare Innovation Conference	November 11	Webcast available
Jefferies London Healthcare Conference	November 19	Webcast available
8th Annual Evercore Healthcare Conference	December 3	Fireside Chat and One-on-one meetings

Webcasts of these fireside chats are made available, and replays are accessible for 90 days following the event, ensuring broad stakeholder access.

Scientific communication through peer-reviewed publications and congresses validates the underlying science. ORIC Pharmaceuticals presented key data at the ESMO Asia Congress 2025 in December 2025. Specifically, data from a Phase 1b trial of enozertinib (ORIC-114) in previously treated NSCLC patients with HER2 exon 20 mutations were presented at a poster session. Furthermore, compelling preliminary data in 1L NSCLC patients with EGFR P-loop and alpha C-helix compressing (PACC) mutations were disclosed. Preclinical work also saw presentation time, with posters on ORIC-944 presented at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics in October 2025. The company also presented ORIC-944 data at the 2025 American Association for Cancer Research (AACR) Annual Meeting in April 2025.

The management of relationships with strategic pharma partners for combination trials is a core part of the development strategy, allowing ORIC Pharmaceuticals to maintain full economic ownership while leveraging partner resources. A key relationship is the clinical trial collaboration and supply agreement with Johnson & Johnson (J&J) to evaluate ORIC-114 in combination with subcutaneous amivantamab for the first-line treatment of NSCLC patients with EGFR exon 20 insertion mutations. The company also leverages strategic collaborations with Bayer. Initial data from this J&J combination trial, along with ORIC-114 monotherapy data in 1L EGFR atypical mutations, are expected in mid-2026. The ORIC-944 program also involves combination studies with AR inhibitors like apalutamide and darolutamide.

Finance: draft 13-week cash view by Friday.

ORIC Pharmaceuticals, Inc. (ORIC) - Canvas Business Model: Channels

The Channels block for ORIC Pharmaceuticals, Inc. centers on disseminating critical clinical progress and maintaining financial transparency with stakeholders while actively managing its global clinical footprint.

Global network of clinical trial sites in North America and Europe

ORIC Pharmaceuticals, Inc. utilizes a network of clinical trial sites to advance its lead candidates, ORIC-944 and enozertinib (ORIC-114). The company is currently enrolling studies across multiple indications, which necessitates a geographically distributed site network, primarily in North America and Europe, given the typical scope of US-headquartered biopharma trials.

• Currently enrolling Phase 1b study of ORIC-944 in prostate cancer with AR inhibitors.
• Currently enrolling Phase 1b/2 study of single-agent enozertinib in EGFR/HER2 mutated NSCLC.
• Currently enrolling Phase 1b study of enozertinib in combination with subcutaneous amivantamab in NSCLC with EGFR exon 20 mutations.

The operational focus is on advancing these programs, supported by $413.0M in cash, cash equivalents, and investments as of the third quarter of 2025. This financial position is projected to fund the operating plan into 2H 2028.

Investor Relations website for financial and pipeline updates

The primary digital channel for investor communication is the Investor Relations section of the corporate website, www.oricpharma.com. This channel delivers formal financial disclosures and pipeline milestones, such as the Q3 2025 financial results reported on November 13, 2025.

Here's a look at the recent financial and pipeline context delivered through this channel:

Metric/Update	Value/Date	Context
Cash, Cash Equivalents, and Investments (Q3 2025)	$413.0M	As of September 30, 2025
Projected Cash Runway	Into 2H 2028	Following strategic pipeline prioritization
Workforce Reduction	Approx. 20%	Streamlining operations to focus on lead programs
ORIC-944 Phase 3 Trial Initiation Target	1H 2026	For metastatic castration-resistant prostate cancer (mCRPC)
ORIC-114 Registrational Trial Initiation Target	2026	Focusing on first-line NSCLC settings

Scientific and medical conferences for data dissemination

Conferences serve as the crucial channel for disseminating primary clinical data to the scientific and medical community. ORIC Pharmaceuticals, Inc. actively presents at key industry events to build scientific credibility for its assets.

• Presented enozertinib (ORIC-114) data at the ESMO Asia Congress 2025 (December 5-7).
• Participated in the 8th Annual Evercore Healthcare Conference on November 24, 2025.
• Management participated in one-on-one meetings at the Guggenheim\'s 2nd Annual Healthcare Innovation Conference (November 11, 2025) and the Jefferies London Healthcare Conference (November 19, 2025).

The data presented at ESMO Asia 2025 included an Overall Response Rate (ORR) of 35% in the enozertinib 80 mg QD cohort for previously treated NSCLC patients with HER2 exon 20 mutations.

Future channel: Specialty pharmaceutical distributors upon commercialization

This channel is currently prospective, contingent upon successful progression through planned late-stage trials. The company is planning to initiate registrational trials for both lead programs in 2026. Upon potential regulatory approval, ORIC Pharmaceuticals, Inc. will need to establish relationships with specialty pharmaceutical distributors to manage the supply chain and market access for its targeted oncology therapies.

ORIC Pharmaceuticals, Inc. (ORIC) - Canvas Business Model: Customer Segments

The customer segments for ORIC Pharmaceuticals, Inc. (ORIC) are defined by the specific patient populations targeted by its clinical pipeline candidates, ORIC-944 and enozertinib (ORIC-114), as well as potential strategic partners.

Oncologists and hematologists treating advanced cancers are key decision-makers and prescribers. Their adoption is influenced by clinical trial results and the potential for best-in-class profiles. As of the third quarter ended September 30, 2025, ORIC Pharmaceuticals had a market capitalization of $1.2B, with a stock price of $12.38 as of November 5, 2025. The company reported cash, cash equivalents and investments totaling $327.7 million as of June 30, 2025. This financial position is expected to fund the operating plan into 2H 2028.

Patients with metastatic castration-resistant prostate cancer (mCRPC) are the target for ORIC-944, a PRC2 inhibitor being tested in combination with androgen receptor pathway inhibitors like apalutamide (ERLEADA) or darolutamide (NUBEQA). The global prostate cancer market is projected to reach $29.2 billion by 2035, with approximately 10% to 20% of all prostate cancers classified as castration-resistant.

Efficacy data from the ongoing Phase 1b trial of ORIC-944 in combination with AR inhibitors for mCRPC patients, with a cutoff date of September 22, 2025, demonstrates the potential value proposition for this segment:

Efficacy Endpoint (ORIC-944 Combination)	Response Rate	Confirmation Status
PSA50 Response Rate	55%	Confirmed in 40%
PSA90 Response Rate	20%	All confirmed

This data is based on patients previously treated with a median of three lines of prior therapy.

Patients with NSCLC having specific EGFR/HER2 exon 20 or atypical mutations are the focus for enozertinib (ORIC-114). The prevalence of these mutations defines the addressable patient pool:

• HER2 exon 20 insertion mutations: observed in approximately 1.5% of all NSCLC patients.
• Atypical EGFR mutations: observed in approximately 2.9% of all NSCLC patients.

For previously treated NSCLC patients with HER2 exon 20 mutations, data presented as of an August 29, 2025 cutoff showed activity:

Dose (Enozertinib QD)	Patients Dosed	Objective Response Rate (ORR)	Disease Control Rate (DCR)
80 mg	26	35% (26% confirmed)	100%
120 mg	23	Not explicitly stated as 35% for this group alone	Not explicitly stated as 100% for this group alone

Enrollment for the HER2 exon 20 mutation population is complete, with no further development planned in that specific group. The 80 mg QD dose was selected for potential Phase 3 development based on data across other EGFR exon 20 and atypical mutation populations. Approximately 47% of the HER2 exon 20 patients at baseline had brain metastases.

Large pharmaceutical companies for potential future licensing/M&A represent a segment for potential non-dilutive financing or commercialization partnerships. ORIC Pharmaceuticals established three strategic partnerships with major pharmaceutical companies as of February 2025. Following a strategic pipeline prioritization, the Company announced it will explore potential partnering of its preclinical programs.

Finance: draft 13-week cash view by Friday.

ORIC Pharmaceuticals, Inc. (ORIC) - Canvas Business Model: Cost Structure

You're looking at the core burn rate for ORIC Pharmaceuticals, Inc. (ORIC) as of late 2025, and honestly, it's what you expect for a clinical-stage biotech: it's almost entirely driven by science.

The Cost Structure for ORIC Pharmaceuticals, Inc. (ORIC) is overwhelmingly dominated by Research & Development (R&D) expenses, which is the engine fueling their pipeline advancement. For the third quarter of 2025, the Total Operating Expenses were reported at \$36.671 million. This figure reflects the necessary investment to push ORIC-944 and enozertinib through their respective clinical stages.

Here's a quick look at how that total operating spend broke down for the quarter ended September 30, 2025:

Expense Category	Q3 2025 Amount (in millions USD)
Total Operating Expenses	\$36.671
Research & Development (R&D) Expenses	\$28.8
General and Administrative (G&A) Expenses	\$7.9

Digging into that R&D spend, you see where the money is actually going to the bench and the bedside. The R&D expenses for the quarter were \$28.8 million. A significant portion of that external spend was dedicated to the enozertinib program, with \$9.0M specifically attributed to external R&D costs for enozertinib in Q3 2025. The internal R&D costs, which include personnel and stock-based compensation, were \$10.3 million for the quarter, and ORIC-944 manufacturing costs were \$5.6 million externally, plus \$3.8 million for preclinical/other external costs. It's all about program advancement, so you need to track those external costs closely.

General and Administrative (G&A) expenses were \$7.9 million in Q3 2025, a slight increase from the prior year, reflecting higher personnel and services costs as the company streamlined operations. Furthermore, this quarter included a specific, non-recurring cost related to that streamlining effort: a one-time charge of \$1.9 million recognized for termination benefits following the workforce reduction. This kind of opex friction is common when a company narrows its focus to lead programs.

You can see the key cost drivers clearly:

• R&D expenses were \$28.8 million for the quarter.
• External costs for enozertinib totaled \$9.0 million.
• G&A was \$7.9 million.
• A one-time charge of \$1.9 million hit the books.

Finance: draft 13-week cash view by Friday.

ORIC Pharmaceuticals, Inc. (ORIC) - Canvas Business Model: Revenue Streams

ORIC Pharmaceuticals, Inc. is currently operating in a pre-revenue phase, meaning product sales are not yet a source of income. For the quarter ended September 30, 2025, the reported Actual Revenue was N/A, which aligns with the reported net loss of $32.6 million for the last quarter.

The primary focus for future revenue generation is centered on the successful clinical progression and eventual commercialization of its two lead product candidates. The company is actively advancing these programs toward potential registrational studies, which is the critical step before generating sales revenue.

Future potential revenue streams are tied directly to these clinical assets:

• ORIC-944: An allosteric inhibitor of the polycomb repressive complex 2 (PRC2), being developed for prostate cancer.
• Enozertinib (ORIC-114): A brain-penetrant inhibitor targeting specific EGFR and HER2 mutations, being developed for multiple genetically defined cancers, including lung cancer.

ORIC Pharmaceuticals expects to report four clinical data readouts across both the ORIC-944 and enozertinib programs through mid-2026, with a potential initiation of registrational trials for both programs targeted in 2026. The World Health Organization has officially recognized 'enozertinib' as its generic name.

Potential milestone payments from strategic licensing or co-development deals represent another non-sales revenue component. While specific deal terms aren't public, the company's focus on advancing these programs to registrational studies suggests that achieving these key clinical milestones could trigger pre-agreed payments from any existing or future partners.

Interest income is derived from the significant balance of cash and investments held on the balance sheet. As of September 30, 2025, ORIC Pharmaceuticals reported cash, cash equivalents, and investments totaling approximately $413 million. This substantial balance is projected to fund the revised operating plan into the second half of 2028 (2H 2028) and beyond the anticipated primary endpoint readouts from the first Phase 3 trials.

Here's a quick look at the financial position supporting this runway:

Financial Metric	Amount (USD Millions)	Period End Date
Cash and Investments Balance	$413.0	September 30, 2025
Research & Development Expenses	$28.8	Three Months Ended September 30, 2025
Cash Runway Projection	Into 2H 2028	As of November 2025

The company has made a prudent decision to substantially reduce investment in discovery research to direct financial resources toward these lead clinical programs.